Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

Authors Donohue JF, Herje N, Crater G, Rickard K

Received 23 April 2014

Accepted for publication 13 June 2014

Published 16 July 2014 Volume 2014:9(1) Pages 745—751

DOI https://doi.org/10.2147/COPD.S44552

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

James F Donohue,1 Nancy Herje,2 Glenn Crater,2 Kathleen Rickard2

1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 2Aerocrine, Inc., Morrisville, NC, USA

Objective: To characterize fractional exhaled nitric oxide (FeNO) levels that may be indicative of Th2-mediated airway inflammation in patients with chronic obstructive pulmonary disease (COPD).
Methods: This single-visit, outpatient study was conducted in 200 patients aged 40 years and older with COPD. All patients underwent spirometry and FeNO testing. COPD severity was classified according to the Global initiative for chronic Obstructive Lung Disease (GOLD) 2010 guidelines.
Results: Patients who participated in the study had a mean age of 63.9±11.3 years and a mean smoking history of 46±29 pack years. Patients had a mean forced expiratory volume in 1 second % predicted of 53.9%±22.1%. The percentage of patients classified with COPD severity Stage I, II, III, and IV was 13%, 40%, 39%, and 8%, respectively. In addition, according to current procedural terminology codes, 32% of patients were classified as mixed COPD/asthma, 26% as COPD/emphysema, and 42% as all other codes. The mean FeNO level for all patients was 15.3±17.2 parts per billion (ppb). Overall, 89% of patients had a FeNO <25 ppb, 8% had a FeNO 25–50 ppb, and 3% had a FeNO >50 ppb. The percentages of patients with FeNO in the intermediate or high ranges of FeNO were greatest among patients with mixed COPD/asthma (intermediate, 11.5%; high, 6.6%) compared with COPD/emphysema (intermediate, 8%; high, 0) and all other codes (intermediate, 6.3%; high, 1.3%).
Conclusion: Increases in FeNO were identified in a subset of patients with COPD, particularly in those previously diagnosed with both COPD and asthma. Since FeNO is useful for identifying patients with airway inflammation who will have a beneficial response to treatment with an inhaled corticosteroid, these data may have important implications for the management of COPD patients.

Keywords: fractional exhaled nitric oxide, chronic obstructive pulmonary disease, asthma, inhaled corticosteroids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:367-381

Published Date: 19 January 2017

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Readers of this article also read:

Caenorhabditis elegans as an alternative in vivo model to determine oral uptake, nanotoxicity, and efficacy of melatonin-loaded lipid-core nanocapsules on paraquat damage

Charão MF, Souto C, Brucker N, Barth A, Jornada DS, Fagundez D, Ávila DS, Eifler-Lima VL, Guterres SS, Pohlmann AR, Garcia SC

International Journal of Nanomedicine 2015, 10:5093-5106

Published Date: 10 August 2015

Self-assembled micelles of amphiphilic poly(L-phenylalanine)-b-poly(L-serine) polypeptides for tumor-targeted delivery

Zhao ZM, Wang Y, Han J, Wang KL, Yang D, Yang YH, Du Q, Song YJ, Yin XX

International Journal of Nanomedicine 2014, 9:5849-5862

Published Date: 12 December 2014

Nanopharmacology in translational hematology and oncology

Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I

International Journal of Nanomedicine 2014, 9:3465-3479

Published Date: 22 July 2014

Efficient gene delivery system mediated by cis-aconitate-modified chitosan-g-stearic acid micelles

Yao JJ, Du YZ, Yuan H, You J, Hu FQ

International Journal of Nanomedicine 2014, 9:2993-3003

Published Date: 18 June 2014

Nanosilver particles in medical applications: synthesis, performance, and toxicity

Ge L, Li Q, Wang M, Ouyang J, Li XJ, Xing MM

International Journal of Nanomedicine 2014, 9:2399-2407

Published Date: 16 May 2014

Comparison of injury incidences between football teams playing in different climatic regions

Orchard JW, Waldén M, Hägglund M, Orchard JJ, Chivers I, Seward H, Ekstrand J

Open Access Journal of Sports Medicine 2013, 4:251-260

Published Date: 5 December 2013